Gilead Sciences Inc

GILD

Company Profile

  • Business description

    Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

  • Contact

    333 Lakeside Drive
    Foster CityCA94404
    USA

    T: +1 650 574-3000

    E: [email protected]

    https://www.gilead.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    17,600

Stocks News & Analysis

stocks

10 cheap wide-moat US stocks for 2025

Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance

US stock market outlook: tariffs are 2025's wild card

Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks

10 cheap US dividend-growth stocks to buy

The stocks of these companies with a history of dividend increases look undervalued today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.4015.50-0.18%
CAC 407,692.493.78-0.05%
DAX 4023,859.8972.440.30%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,801.5821.33-0.24%
HKSE23,794.91121.15-0.51%
NASDAQ20,601.10207.971.02%
Nikkei 22539,587.68223.20-0.56%
NZX 50 Index12,764.951.65-0.01%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,589.3013.70-0.16%
SSE Composite Index3,473.130.810.02%

Market Movers